Pharsight

Vocabria is owned by Viiv Hlthcare.

Vocabria contains Cabotegravir Sodium.

Vocabria has a total of 2 drug patents out of which 0 drug patents have expired.

Vocabria was authorised for market use on 21 January, 2021.

Vocabria is available in tablet;oral dosage forms.

Vocabria can be used as treatment of hiv-1 in an adult in combination with rilpivirine.

Drug patent challenges can be filed against Vocabria from January, 2025.

The generics of Vocabria are possible to be released after 28 April, 2026.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410103	VIIV HLTHCARE	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr, 2026 (3 years from now)
US10927129	VIIV HLTHCARE	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr, 2026 (3 years from now)